Literature DB >> 17052995

Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

Xiaochao Ma1, Jeffrey R Idle, Michael A Malfatti, Kristopher W Krausz, Daniel W Nebert, Chong-Sheng Chen, James S Felton, David J Waxman, Frank J Gonzalez.   

Abstract

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis is initiated by N(2)-hydroxylation, mediated by several cytochromes P450, including CYP1A1. However, the role of CYP1A1 in PhIP metabolic activation in vivo is unclear. In this study, Cyp1a1-null and wild-type (WT) mice were used to investigate the potential role of CYP1A1 in PhIP metabolic activation in vivo. PhIP N(2)-hydroxylation was actively catalyzed by lung homogenates of WT mice, at a rate of 14.9 +/- 5.0 pmol/min/g tissue, but <1 pmol/min/g tissue in stomach and small intestine, and almost undetectable in mammary gland and colon. PhIP N(2)-hydroxylation catalyzed by lung homogenates of Cyp1a1-null mice was approximately 10-fold lower than that of WT mice. In contrast, PhIP N(2)-hydroxylation activity in lung homogenates of Cyp1a2-null versus WT mice was not decreased. Pretreatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin increased lung Cyp1a1 mRNA and lung homogenate PhIP N(2)-hydroxylase activity approximately 50-fold in WT mice, where the activity was substantially inhibited (70%) by monoclonal antibodies against CYP1A1. In vivo, 30 min after oral treatment with PhIP, PhIP levels in lung were similar to those in liver. After a single dose of 0.1 mg/kg [(14)C]PhIP, lung PhIP-DNA adduct levels in Cyp1a1-null mice, but not in Cyp1a2-null mice, were significantly lower (P = 0.0028) than in WT mice. These results reveal that mouse lung has basal and inducible PhIP N(2)-hydroxylase activity predominantly catalyzed by CYP1A1. Because of the high inducibility of human CYP1A1, especially in cigarette smokers, the role of lung CYP1A1 in PhIP carcinogenesis should be considered. (237 words).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052995      PMCID: PMC1829392          DOI: 10.1093/carcin/bgl184

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  45 in total

1.  Inhibitory effects of beer on mutation in the Ames test and DNA adduct formation in mouse organs induced by 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).

Authors:  Sakae Arimoto-Kobayashi; Rie Ishida; Yumi Nakai; Chiho Idei; Jun Takata; Eizo Takahashi; Keinosuke Okamoto; Tomoe Negishi; Toshimitsu Konuma
Journal:  Biol Pharm Bull       Date:  2006-01       Impact factor: 2.233

2.  Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery.

Authors:  T P Dalton; M Z Dieter; R S Matlib; N L Childs; H G Shertzer; M B Genter; D W Nebert
Journal:  Biochem Biophys Res Commun       Date:  2000-01-07       Impact factor: 3.575

3.  Differential enzyme induction of mouse liver and lung following a single low or high dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Authors:  L Beebe; S S Park; L M Anderson
Journal:  J Biochem Toxicol       Date:  1990

4.  Excretion of the N(2)-glucuronide conjugate of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in urine and its relationship to CYP1A2 and NAT2 activity levels in humans.

Authors:  W G Stillwell; R Sinha; S R Tannenbaum
Journal:  Carcinogenesis       Date:  2002-05       Impact factor: 4.944

5.  Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes.

Authors:  G J Hammons; D Milton; K Stepps; F P Guengerich; R H Tukey; F F Kadlubar
Journal:  Carcinogenesis       Date:  1997-04       Impact factor: 4.944

6.  Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human.

Authors:  R J Edwards; B P Murray; S Murray; T Schulz; D Neubert; T W Gant; S S Thorgeirsson; A R Boobis; D S Davies
Journal:  Carcinogenesis       Date:  1994-05       Impact factor: 4.944

7.  Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP.

Authors:  B P Murray; R J Edwards; S Murray; A M Singleton; D S Davies; A R Boobis
Journal:  Carcinogenesis       Date:  1993-04       Impact factor: 4.944

8.  Metabolism of heterocyclic aromatic amines by human hepatocytes and cytochrome P4501A2.

Authors:  Robert J Turesky; F Peter Guengerich; André Guillouzo; Sophie Langouët
Journal:  Mutat Res       Date:  2002-09-30       Impact factor: 2.433

9.  Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice.

Authors:  Christopher A Wiwi; Minita Gupte; David J Waxman
Journal:  Mol Endocrinol       Date:  2004-05-20

10.  Localization of CYP1A1 mRNA in human lung by in situ hybridization: comparison with immunohistochemical findings.

Authors:  S T Saarikoski; K Husgafvel-Pursiainen; A Hirvonen; H Vainio; F J Gonzalez; S Anttila
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

View more
  11 in total

1.  A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach.

Authors:  Chi Chen; Xiaochao Ma; Michael A Malfatti; Kristopher W Krausz; Shioko Kimura; James S Felton; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2007-02-06       Impact factor: 3.739

Review 2.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Authors:  Daniel W Nebert; Timothy P Dalton
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

3.  Generation of a 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor.

Authors:  Zhanquan Shi; Ying Chen; Hongbin Dong; Robyn M Amos-Kroohs; Daniel W Nebert
Journal:  Biochem Biophys Res Commun       Date:  2008-09-22       Impact factor: 3.575

4.  Intakes of red meat, processed meat, and meat mutagens increase lung cancer risk.

Authors:  Tram Kim Lam; Amanda J Cross; Dario Consonni; Giorgia Randi; Vincenzo Bagnardi; Pier Alberto Bertazzi; Neil E Caporaso; Rashmi Sinha; Amy F Subar; Maria Teresa Landi
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

5.  Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: differing responses to dietary benzo[a]pyrene as proof of principle.

Authors:  Hongbin Dong; Timothy P Dalton; Marian L Miller; Ying Chen; Shigeyuki Uno; Zhanquan Shi; Howard G Shertzer; Seema Bansal; Narayan G Avadhani; Daniel W Nebert
Journal:  Mol Pharmacol       Date:  2008-12-01       Impact factor: 4.436

6.  Novel Transgenic Mouse Model for Studying Human Serum Albumin as a Biomarker of Carcinogenic Exposure.

Authors:  Jonathan Sheng; Yi Wang; Robert J Turesky; Kerri Kluetzman; Qing-Yu Zhang; Xinxin Ding
Journal:  Chem Res Toxicol       Date:  2016-04-14       Impact factor: 3.739

7.  Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins.

Authors:  Hongbin Dong; Howard G Shertzer; Mary Beth Genter; Frank J Gonzalez; Vasilis Vasiliou; Colin Jefcoate; Daniel W Nebert
Journal:  Biochem Biophys Res Commun       Date:  2013-05-18       Impact factor: 3.575

8.  Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts.

Authors:  J Bendaly; K J Metry; M A Doll; G Jiang; J C States; N B Smith; J R Neale; J L Holloman; W M Pierce; D W Hein
Journal:  Xenobiotica       Date:  2009-05       Impact factor: 1.908

9.  Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut.

Authors:  Shinji Ito; Chi Chen; Junko Satoh; Sunhee Yim; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 10.  Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.

Authors:  Vasilis P Androutsopoulos; Aristidis M Tsatsakis; Demetrios A Spandidos
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.